Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.